Pharmaceutical Executive Europe - February 2008 - (Page 4)

4 From the Editor February 2008 Pharmaceutical Executive Europe Pharmaceutical Executive Advancing business leadership Make Your Move A s you’ll read in the pages that follow, European pharma is still very preoccupied with the EU’s dawn raids on 16 January, Commissioner for competition Neelie Kroes’s little New Year gift to the industry. Kroes’s suspicion that Big Pharma is engaging in anti-competitive behaviour sent shock waves across the industry. The raids constituted a high-profile and some say Draconian move, but what does it actually mean? The arguments that follow range from the cautiously positive — Kroes’s campaign has the interests of patients at heart — to the downright sceptical: that is, this ‘get tough’ attitude is unlikely to actually see any acceleration in the innovation process. Whatever the outcome, we await the EU’s next move with some trepidation. A note on some upcoming Pharm Exec Europe activities: we will be present at the DIA EuroMeeting in Barcelona in March, and I would love to see you if you’re planning to attend. It could provide a perfect opportunity to give me your feedback on the publication’s shift to its new digital platform, and anything else you’d like to talk about. The EuroMeeting is always essential for ‘putting faces to names’ and receiving constructive feedback on the direction and quality of Pharm Exec Europe’s content. Please drop by Stand 165 — I’ll be happy to meet you. Also next month, Pharm Exec Europe’s first White Paper will be available exclusively to subscribers. Taking an in-depth look at how pharma competes in Europe, the paper explores the use of competitive strategies, how to tap into 'open innovation' in Europe, how to acquire in-depth knowledge of markets and how to build successful co-marketing arrangements. Written by our new EAB member Gerhard Symons, the paper will be essential reading for anyone involved in senior decision-making and competitive strategy in pharma. I look forward to letting Julian Upton you know about further White Papers in the coming months. Pharmaceutical Executive Europe provides industry intelligence so managers in the European pharmaceutical community can advance their business, management and marketing practices to gain competitive advantage. PEE interprets the current and future challenges the industry faces and enables pharmaceutical professionals to overcome them with cost-effective, time-saving solutions. Group Publisher Andy Davies Tel. +44 1244 393 408 Editorial Director Peter Houston Tel. +44 1244 393 435 Editor Julian Upton Associate Editor Victoria Farrell Marketing Manager Sally Carron Associate Publisher Kevin McGeehan Sales Support Claire Rice Graphic Designer Ian Williams Production Director Jo Armstrong Repro Art Worker Alan James Advanstar Communications (U.K.) Ltd Managing Director Helen Gardner Corporate Office Advanstar Communications Inc. 7500 Old Oak Boulevard Cleveland OH 44130, USA Advanstar Communications Inc. Chief Executive Officer Joseph Loggia Chief Financial Officer Theodore S. Alpert Chief Marketing Officer Patricia Joseph Executive VP, Corporate Development Eric I. Lisman VP, Treasurer & Controller Shelbie O’Brien VP, Publishing Operations Francis Heid VP, Human Resources Nancy Nugent VP, Chief Technology Officer Rick Treese VP, Marketing & Communications Georgiann Decenzo VP, General Counsel Ward Hewins Subscribe online at Pharmaceutical Executive Europe is free to qualified subscribers in Europe. To apply for a free subscription, or to change your name or address, go to, click on Subscribe, & follow the prompts. To cancel your subscription or to order back issues, please email your request to, putting PEE in the subject line. Please quote your subscription number if you have it Non-qualified readers in Europe Readers outside Europe 1 year (8 issues) £100 £140 2 years (16 issues) £170 £240 Current issue: Back issue: £20 £35 Copyright ©2008. Advanstar Communications (UK) Ltd. All rights reserved. No part of this publication may be reproduced in any material form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other use of this publication) without the written permission of the copyright owner except in accordance with the provisions of the Copyright, Designs & Patents Act (UK) 1988 or under the terms of a licence issued by the Copyright Licensing Agency, 90 Tottenham Court Road, London W1P 0LP UK. , Applications for the copyright owner’s permission to reproduce any part of this publication should be forwarded in writing to Permissions Dept, Advanstar Communications (UK) Ltd, Advanstar House, Park West, Sealand Road, Chester CH1 4RN, UK. Warning: The doing of an unauthorized act in relation to a copyright work may result in both a civil claim for damages and criminal prosecution. Editorial Advisory Board Pharmaceutical Executive Europe’s Editorial Advisory Board (EAB) is a distinguished group of specialists who represent various facets of the pharmaceutical industry. EAB members suggest article subjects relevant to the industry, review article manuscripts, participate in events and answer questions as they arise. CSR Francis P. Crawley Executive Director General, Good Clinical Practice Alliance Biopartnering Gerhard Symons Doctoral Researcher, Taneka Business School, Imperial College, London Branding Rebecca Robins Global Marketing Director, Interbrand Wood Healthcare Business/Marketing Steve Mackenzie-Lawrie Consultant, SML Associates Executive/Strategy David Barratt Managing Director, Lowe Azure, Lowe Fusion and ICC Europe Medical Education Peter George CEO, Penn Pharmaceutical Services Business/Marketing Keith Allan Head of Global Product Advocacy, Novartis Pharma Clinical Trials Nathan Waller Director, Account Management, PAREXEL International Supply Chain Julian Mount Senior Director, Head of European Trade, Pfizer Outsourcing Andy Parrett European Outsource Manager, Mundipharma Research Ltd

Table of Contents for the Digital Edition of Pharmaceutical Executive Europe - February 2008

Pharmaceutical Executive Europe - February 2008
From the Editor
News and Analysis
Brussels Report
R&D: Innovation - Learning to Share
Drug Launch - The Preparation Game
Q&A - Getting a Head Start
Regulatory Compliance - Credible Compliance
Clinical Trials - Establishing Trials in China
The Mix - Relevant ROI
Comment - Taming the Trader
Last Word - Under the Microscope

Pharmaceutical Executive Europe - February 2008